National Stem Cell Holding, Inc. (Pink Sheets:NHGI) announced that Michael Cohen, CEO, is the author of the featured Viewpoint piece today on the front page of BusinessWeek online: www.businessweek.com. The article is also in the lead position on the Technology and Science landing page www.businessweek.com/technology.

In the opinion piece, Mr. Cohen discusses the issue of government funding for umbilical cord blood collection, a critical source of adult stem cells.

National Stem Cell Holding, Inc. is a biotechnology company headquartered in New York City dedicated to the advancement of regenerative medicine. Through its sponsored research agreement with the Johns Hopkins University School of Medicine's Institute for Cell Engineering, National Stem Cell is focused on the development of potential stem cell therapies for the treatment of diabetes and cardiac injury. The company is developing a genetically diverse umbilical cord blood bank to meet the growing need for transplant grade umbilical cord blood stem cells. National Stem Cell Holding, Inc. is the parent company of National Stem Cell, Inc., incorporated in 2005, which operates the Sperm Bank of New York as a wholly owned subsidiary. For more information, please visit www.nationalstemcell.com.